Brain Scientific Inc. (BRSF) Disrupts Expensive EEG Market
- 70% of those with epilepsy could live seizure-free lives if properly diagnosed, treated
- Machine-learning algorithms using EEG signals have potential to accurately predict epileptic seizures, allowing patient to take preventive measures
- NeuroCap provides cost-effective solution that is disrupting EEG market
Brain Scientific (OTCQB: BRSF) is modernizing brain diagnostics with cutting-edge technology that bridges the widening gap in access to quality care. The use of artificial intelligence (“AI”) and machine learning (“ML”) is at the forefront of improving epileptic patients’ access to neurological care.
According to the World Health Organization (“WHO”), 50 million people worldwide have epilepsy (https://nnw.fm/45dYv). Approximately 70% of those people could live seizure-free lives if properly diagnosed and treated. Seizures are controllable. Through a pilot program, WHO discovered that by merely training primary health-care providers to diagnose and treat epilepsy, more people would have access to the treatment they need.
However, with conventional methods the necessary diagnostic equipment is cumbersome, complicated, and expensive; it also requires a trained technician to administer the tests. A more portable, simple-to-administer test is needed to reach the majority worldwide.
In the United States alone, an estimated 2.3 million adults and more than 450,000 children and adolescents live with epilepsy, with an estimated 150,000 people diagnosed each year (https://nnw.fm/V09rK). Tragically, access to neurological care is decreasing as the need grows. In 2017, 20 states were considered neurology deserts, meaning they had less than 10 neurologists per 10,000 patients (https://nnw.fm/MUogD).
A 2019 Advisory Board brief, titled “Navigating the Neurologist Shortage,” reported that the situation was not improving (https://nnw.fm/02RXl). “Providers across the country currently struggle to hire neurologists—and the problem shows no sign of abating. Estimates show that demand for neurologists in 2025 will exceed supply by 19%,” the report observed. This makes the wait for essential diagnosis and treatment long — and sometimes dangerous.
The solution may well be BRSF’s neuro-tech ecosystem. This approach consists of the disposable NeuroCap(TM) and a portable wireless NeuroEEG(TM) amplifier. These products provide rural hospitals with easy access to EEG tests.
Machine learning has improved EEG analysis and solved several challenges. Brain Scientific is working on incorporating AI and machine learning processes into the analysis, which will be able to free neurologists from the manual, tedious, and time-consuming portions of their jobs, thereby allowing them to help more patients.
According “Machine Learning for Predicting Epileptic Seizures Using EEG Signals,” which was published in February 2020, when an epileptic seizure is predicted in advance it is possible to take preventative interventions (https://nnw.fm/uwgpj). Machine learning algorithms using EEG signals have the potential to accurately predict epileptic seizures. This state-of-the-art hope for epilepsy still has problems, “cost-effective and efficient hardware implementation remains the bottleneck.”
Brain Scientific is working to disrupt the expensive EEG market. The NeuroCap and NeuroEEG are both approved by the FDA and provide economic and disposable substitutes. Trained technicians are not required to administer the tests, and a neurologist does not have to be on-site to run the analysis. A telemedicine physician can read the results in real time, eliminating long waits, high costs and the risks of exposure to communicable diseases such as COVID.
Brain Scientific is working to make neurological care accessible for all who need it.
For more information, visit the company’s website at www.BrainScientific.com.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://nnw.fm/BRSF
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- 70% of those with epilepsy could live seizure-free lives if properly diagnosed, treated
- Machine-learning algorithms using EEG signals have potential to accurately predict epileptic seizures, allowing patient to take preventive measures
- NeuroCap provides cost-effective solution that is disrupting EEG market
Brain Scientific (OTCQB: BRSF) is modernizing brain diagnostics with cutting-edge technology that bridges the widening gap in access to quality care. The use of artificial intelligence (“AI”) and machine learning (“ML”) is at the forefront of improving epileptic patients’ access to neurological care.
According to the World Health Organization (“WHO”), 50 million people worldwide have epilepsy (https://nnw.fm/45dYv). Approximately 70% of those people could live seizure-free lives if properly diagnosed and treated. Seizures are controllable. Through a pilot program, WHO discovered that by merely training primary health-care providers to diagnose and treat epilepsy, more people would have access to the treatment they need.
However, with conventional methods the necessary diagnostic equipment is cumbersome, complicated, and expensive; it also requires a trained technician to administer the tests. A more portable, simple-to-administer test is needed to reach the majority worldwide.
In the United States alone, an estimated 2.3 million adults and more than 450,000 children and adolescents live with epilepsy, with an estimated 150,000 people diagnosed each year (https://nnw.fm/V09rK). Tragically, access to neurological care is decreasing as the need grows. In 2017, 20 states were considered neurology deserts, meaning they had less than 10 neurologists per 10,000 patients (https://nnw.fm/MUogD).
A 2019 Advisory Board brief, titled “Navigating the Neurologist Shortage,” reported that the situation was not improving (https://nnw.fm/02RXl). “Providers across the country currently struggle to hire neurologists—and the problem shows no sign of abating. Estimates show that demand for neurologists in 2025 will exceed supply by 19%,” the report observed. This makes the wait for essential diagnosis and treatment long — and sometimes dangerous.
The solution may well be BRSF’s neuro-tech ecosystem. This approach consists of the disposable NeuroCap(TM) and a portable wireless NeuroEEG(TM) amplifier. These products provide rural hospitals with easy access to EEG tests.
Machine learning has improved EEG analysis and solved several challenges. Brain Scientific is working on incorporating AI and machine learning processes into the analysis, which will be able to free neurologists from the manual, tedious, and time-consuming portions of their jobs, thereby allowing them to help more patients.
According “Machine Learning for Predicting Epileptic Seizures Using EEG Signals,” which was published in February 2020, when an epileptic seizure is predicted in advance it is possible to take preventative interventions (https://nnw.fm/uwgpj). Machine learning algorithms using EEG signals have the potential to accurately predict epileptic seizures. This state-of-the-art hope for epilepsy still has problems, “cost-effective and efficient hardware implementation remains the bottleneck.”
Brain Scientific is working to disrupt the expensive EEG market. The NeuroCap and NeuroEEG are both approved by the FDA and provide economic and disposable substitutes. Trained technicians are not required to administer the tests, and a neurologist does not have to be on-site to run the analysis. A telemedicine physician can read the results in real time, eliminating long waits, high costs and the risks of exposure to communicable diseases such as COVID.
Brain Scientific is working to make neurological care accessible for all who need it.
For more information, visit the company’s website at www.BrainScientific.com.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://nnw.fm/BRSF
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
